CN106668062A - Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage - Google Patents
Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage Download PDFInfo
- Publication number
- CN106668062A CN106668062A CN201710058906.2A CN201710058906A CN106668062A CN 106668062 A CN106668062 A CN 106668062A CN 201710058906 A CN201710058906 A CN 201710058906A CN 106668062 A CN106668062 A CN 106668062A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- medicinal composition
- wound healing
- zinc sulfate
- oxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
Abstract
The invention provides a medicinal composition, application of the medicinal composition to preparation of a medicament for wound healing, a medical preparation and a medical bandage. The medicinal composition comprises an oxidizing agent, zinc sulfate and water. The medicinal composition not only is added with the oxidizing agent serving as an ingredient for promoting tissue repair and regeneration, but also comprises a zinc sulfate ingredient. Zinc can keep a normal physiological function of epithelial cells, inhibit hyperkeratosis of the epithelial cells and enables the epithelial cells to be normally repaired; meanwhile, the zinc also has a function of reinforcing the body immunity, plays an effect of defending infection, and has important effects on multiplication of fiber cells and collagen synthesis. The zinc sulfate and the oxidizing agent are used as the ingredients of the medicinal composition together, so that the medicinal composition not only has an excellent effect of killing bacteria, fungi and spore, but also has an obvious effect of promoting wound healing. Moreover, the ingredients used by the medicinal composition are all low in price and wide in source, and the medicinal composition is a wound healing auxiliary medicament with low cost and excellent effects.
Description
Technical field
The present invention relates to pharmaceutical technology field, in particular to a kind of pharmaceutical composition, it heals preparing for wound
Application, pharmaceutical preparation and medical binder in the medicine of conjunction.
Background technology
Wound pain brings very big pain, most patients to mitigate wound pain, many institutes by injecting anesthetic medicine to patient
The more narcotics of known injection have certain harm to body；At present postoperative patient's wound is wrapped up using medicine sand cloth,
Secretions produced by wound circumference cause it is airtight, cause wound out-of-flatness, unsightly, be difficult healing.Wound is in Sha Bubao
Under pricking closed environment, possess the temperature conditionss of the moist and body temperature of wound leachate, time length is easily grown on the contrary
A large amount of antibacterials, cause wound infection, and this has just delayed the healing of wound.
At present, Clinical Processing wound such as knife injury, the method for burn mainly have suture, debridement, skin transplantation and infection etc.
Remedy measures, still lack the effective ways of accelerating wound healing.Recently various somatomedin of research report can promote wound to heal
Close, these materials are not only expensive, wherein it is important that dosage and safety problem are also in experimental stage, therefore, develop a kind of
The medicine tool of the good treatment skin trauma of safety, clinical efficacy is of great significance.
Based on above reason, it is necessary to provide a kind of medicine cheap, that wound healing can be promoted.
The content of the invention
Present invention is primarily targeted at provide a kind of pharmaceutical composition, its prepare for wound healing medicine in
Using, pharmaceutical preparation and medical binder, to solve prior art in wound indolence, expensive problem.
To achieve these goals, according to an aspect of the invention, there is provided a kind of pharmaceutical composition, it includes oxidation
Agent, zinc sulfate and water.
Further, oxidant is one or more in ozone, hypochlorous acid, hydrochloric acid and hydrogen peroxide, preferred oxidant
For hypochlorous acid.
Further, the weight percentage of oxidant is 0.001~0.05%, and the weight percentage of zinc sulfate is
0.25~3%.
Further, the weight ratio between zinc sulfate and oxidant is 60~250:1.
Further, the pH value of pharmaceutical composition is 2~6.
Further, the pH value of pharmaceutical composition is 4~5.
Further, by weight percentage, pharmaceutical composition also includes 0.85~0.9% halide salt.
Further, halide salt is one or more in Sodium Chloride, potassium chloride and zinc chloride.
According to a further aspect in the invention, there is provided a kind of above-mentioned pharmaceutical composition is preparing the medicine for wound healing
Application in thing.
According to a further aspect in the invention, there is provided a kind of pharmaceutical preparation, including container, wherein, be packaged with container
The pharmaceutical composition stated, and there is no chemical reaction between container and pharmaceutical composition.
According to a further aspect in the invention, there is provided a kind of medical binder, including binder body, wherein, binder body
Side is provided with opening, and the encapsulation part of repeatable opening is provided with opening, and is loaded with above-mentioned pharmaceutical composition in being open.
Using technical scheme, there is provided a kind of pharmaceutical composition, it includes oxidant, zinc sulfate and water.Should
Pharmaceutical composition be different from traditional aqueous oxidizing agent solution, not only with the addition of oxidant as tissue repair and regenerate promotion into
Point, further comprises zinc sulfate composition.Zinc is able to maintain that the normal physiological function of epithelial cell, suppresses epithelial cell hyperkeratosiss,
Epithelial cell is set normally to repair；Meanwhile, it also has the function of enhancing human body immunity, plays the effect of defence infection, and to fiber
The hypertrophy of cell, collage synthesis all play an important role.By zinc sulfate and oxidant collectively as pharmaceutical composition composition so that should
Pharmaceutical composition except with the good effect for killing antibacterial, funguses, spore, also with the work for being obviously promoted wound healing
With.Additionally, composition used by the pharmaceutical composition is cheap, wide material sources are that a kind of excellent wound of inexpensive, effect is healed
Close ancillary drug.
Specific embodiment
It should be noted that in the case where not conflicting, the feature in embodiment and embodiment in the application can phase
Mutually combination.The present invention is described in detail below in conjunction with embodiment.
The application is described in further detail below in conjunction with specific embodiment, these embodiments are it is not intended that limit this
Apply for scope required for protection.
It is of the prior art to promote the medicine of wound healing to act on slow, price as described by background section
It is expensive.In order to solve this problem, the invention provides a kind of pharmaceutical composition, it includes oxidant, zinc sulfate and water.
The aforementioned pharmaceutical compositions that the present invention is provided are different from traditional aqueous oxidizing agent solution, not only with the addition of oxidant work
For tissue repair and the promotion composition of regeneration, zinc sulfate composition is further comprises.Zinc sulfate is skin and mucous membrane disinfection agent, and it has controls
Treat ulcer, promote wound healing effect.Zinc can maintain the normal physiological function of epithelial cell, suppress epithelial cell hyperkeratosiss,
Epithelial cell is set normally to repair.It also has the function of enhancing human body immunity, plays the effect of defence infection, and to fibrocellular
Hypertrophy, collage synthesis all play an important role.By zinc sulfate and oxidant collectively as pharmaceutical composition composition so that the medicine group
Compound except with the good effect for killing antibacterial, funguses, spore, also with the effect for being obviously promoted wound healing.This
Outward, composition used by the pharmaceutical composition is cheap, wide material sources, is that a kind of excellent wound healing of inexpensive, effect is auxiliary
Help medicine.It has application prospect widely in terms of the skin injurys such as incision, lacerated wound, burn and scald and ulcer.
In addition, zinc sulfate is skin and mucous membrane disinfection medicine, and zinc is biological indispensable trace element in vivo, in human body
The activity of interior wide participation enzyme, is also micro necessary to nucleic acid metabolism, protein synthesis, glycolysiss and phosphorous oxide conversion process
Element.Zinc sulfate can also block receptor on mast cell membrane, its degranulation reaction be controlled, with anti-allergic effects.
In a preferred embodiment, oxidant is the one kind or many in ozone, hypochlorous acid, hydrochloric acid and hydrogen peroxide
Kind.This several oxidant is oxidant relevant with wound healing, tissue repair regeneration in physiological system.As in the present invention
State the oxidant in pharmaceutical composition, its in addition to it can promote wound healing, also with stimulating little advantage.More preferably oxygen
Agent is hypochlorous acid.Sterilization processing of the hypochlorous acid for middle granulocyte in inflammation, the wound location damaged has significant effect.
In a preferred embodiment, the weight percentage of oxidant is 0.001~0.05%, the weight of zinc sulfate
Amount percentage composition is 0.25~3%.The weight percentage of oxidant and zinc sulfate is controlled within the above range, one can be entered
Step improves the healing rate of wound.Meanwhile, the weight percentage of zinc sulfate is controlled within the above range, itself and protein are tied
Close more firmly, with stronger astriction and bacteriostasis.Using the pharmaceutical composition of the concentration, the knot after wound is processed
Scar elastic force and toughness are good, soft abrasion-resistant.In a word, while speed of wound healing is improved the cicatrix after healing can be made thin
It is micro-.
In a preferred embodiment, the weight ratio between zinc sulfate and oxidant is 60~250:1.Will the two it
Between weight than control within the above range, further forward direction cooperative effect can be played, obtain 1+1>2 further have
Beneficial effect.The speed of wound healing faster, meanwhile, the cicatrix after healing is trickleer.
In a preferred embodiment, the pH value of pharmaceutical composition is 2~6.The pH value of pharmaceutical composition is controlled
For 2~6, closer to the pH demands of human physiological environment.It is highly preferred that pH value is 4~5.The pH be 4~5 under conditions of, oxidation
Agent and zinc sulfate can more fully play sterilization, promote the effect of wound healing, make the medicinal effects of solution more preferably.
In a preferred embodiment, by weight percentage, pharmaceutical composition also includes 0.85~0.9% halogen
Salt dissolving.Halide salt is added, the electrolyte of wound body fluid seepage loss can be further supplemented so as to more preferable physiological equilibrium
Ability.Certainly, the halide salt can select type commonly used in the art.In a preferred embodiment, halide salt is chlorine
Change one or more in sodium, potassium chloride and zinc chloride, it is highly preferred that halide salt is Sodium Chloride.
According to a further aspect in the invention, there is provided a kind of above-mentioned pharmaceutical composition is preparing the medicine for wound healing
Application in thing.
The pharmaceutical composition provided using the present invention is preparing the medicine for wound healing, aforementioned pharmaceutical compositions difference
In traditional aqueous oxidizing agent solution, oxidant is not only with the addition of as tissue repair and the promotion composition of regeneration, further comprises sulfur
Sour zinc composition.Zinc sulfate is skin and mucous membrane disinfection agent, and it has treatment ulcer, promotes wound healing effect.Zinc can maintain epithelium
The normal physiological function of cell, suppresses epithelial cell hyperkeratosiss, epithelial cell is normally repaired.It also has enhancing human body immunity
Function, play the effect of defence infection, and fibrocellular hypertrophy, collage synthesis are all played an important role.By zinc sulfate with
Oxidant is collectively as pharmaceutical composition composition so that the pharmaceutical composition is except with good killing antibacterial, funguses, spore
Effect, also with the effect for being obviously promoted wound healing.Additionally, composition used by the pharmaceutical composition is cheap, come
Source is a kind of excellent wound healing ancillary drug of inexpensive, effect extensively.It is in incision, lacerated wound, burn and scald and ulcer
Deng skin injury aspect with application prospect widely.
According to a further aspect in the invention, there is provided a kind of pharmaceutical preparation, including container, wherein, be packaged with container
The pharmaceutical composition stated, and there is no chemical reaction between container and pharmaceutical composition.
According to a further aspect in the invention, there is provided a kind of medical binder, including binder body, wherein, binder body
Side is provided with opening, and the encapsulation part of repeatable opening is provided with opening, and is loaded with above-mentioned pharmaceutical composition in being open.
Thus, when in use can open encapsulation part, alignment wound at the opening of above-mentioned pharmaceutical composition will be loaded with and be attached to
On its surface, to reach the effect for promoting wound healing.
Beneficial effects of the present invention are further illustrated by the following examples：
Embodiment 1 to 8 and comparative example 1 to 2
The pharmaceutical composition of different component, the composition of each pharmaceutical composition are configured with embodiment 1 to 8 and comparative example 1 to 2
And content (weight percentage) is as follows：
Table 1
Wound healing assay：
Close from physique, the adult mice of health in different mice back manufacture incised wounds, and artificially manufactures wound office
Portion infects and causes to infect, the unclean environment rich in pathogenic bacterium is (including escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus
Bacterium, staphylococcus epidermidiss, Candida albicans, aspergillus niger, enterococcus faecalis, mycoplasma, chlamydia and ameba).To implement
Pharmaceutical composition in example 1 to 8 and comparative example 1 and 2 is sprayed at respectively on the wound of different mice back, twice a day.Not
With observing after time interval, upper rear healing state is as follows：
Table 2
From above-mentioned data, the pharmaceutical composition of present invention offer is employed in embodiment 1 to 8, wherein contain simultaneously
Oxidant and zinc sulfate.It is sprayed on mice wound, can be effectively suppressed wound infection, and is accelerated speed of wound healing.
And only contain hypochlorous acid in the pharmaceutical composition of comparative example 1, in unclean environment, hypochlorous acid is played and volatilized quickly after bactericidal action
Decompose, antibacterial is quickly invaded again in unclean environment, cause infection to exist repeatedly, wound protracted course of disease.Adopt in comparative example 2
Drug regimen in only contain zinc sulfate, although its can wound surface formed albuminous coat, its speed of wound healing mistake
It is low.
Especially, the weight percentage of oxidant is 0.001~0.05% in embodiment 1 and 2, the weight hundred of zinc sulfate
It is 60~250 to divide content for the weight ratio between 0.25~3%, and zinc sulfate and oxidant:1, pH is 4 to 5.Using the medicine
Compositionss can further promote wound healing, and the cicatrix flat smooth no color differnece after healing.
As can be seen from the above description, the above embodiments of the present invention realize following technique effect：The present invention is carried
For pharmaceutical composition, it includes oxidant, zinc sulfate and water.The pharmaceutical composition is different from traditional aqueous oxidizing agent solution,
Oxidant not only be with the addition of as tissue repair and the promotion composition of regeneration, zinc sulfate composition is further comprises.Zinc is able to maintain that
The normal physiological function of chrotoplast, suppresses epithelial cell hyperkeratosiss, epithelial cell is normally repaired；Meanwhile, it also strengthens
The function of immunity of organism, plays the effect of defence infection, and fibrocellular hypertrophy, collage synthesis are all played an important role.Will
Zinc sulfate and oxidant are collectively as pharmaceutical composition composition so that the pharmaceutical composition except with good killing antibacterial,
Funguses, the effect of spore, also with the effect for being obviously promoted wound healing.Additionally, composition average price used by the pharmaceutical composition
Lattice are cheap, wide material sources, are a kind of excellent wound healing ancillary drugs of inexpensive, effect.
The preferred embodiments of the present invention are the foregoing is only, the present invention is not limited to, for the skill of this area
For art personnel, the present invention can have various modifications and variations.It is all within the spirit and principles in the present invention, made any repair
Change, equivalent, improvement etc., should be included within the scope of the present invention.
Claims (11)
1. a kind of pharmaceutical composition, it is characterised in that including oxidant, zinc sulfate and water.
2. pharmaceutical composition according to claim 1, it is characterised in that the oxidant be ozone, hypochlorous acid, hydrochloric acid and
One or more in hydrogen peroxide, the preferably oxidant are hypochlorous acid.
3. pharmaceutical composition according to claim 2, it is characterised in that the weight percentage of the oxidant is
0.001~0.05%, the weight percentage of the zinc sulfate is 0.25~3%.
4. pharmaceutical composition according to claim 3, it is characterised in that the weight between the zinc sulfate and the oxidant
Amount is than being 60~250:1.
5. pharmaceutical composition according to any one of claim 1 to 3, it is characterised in that the pH of described pharmaceutical composition
It is worth for 2~6.
6. pharmaceutical composition according to claim 5, it is characterised in that the pH value of described pharmaceutical composition is 4~5.
7. pharmaceutical composition according to claim 5, it is characterised in that by weight percentage, described pharmaceutical composition
Also include 0.85~0.9% halide salt.
8. pharmaceutical composition according to claim 7, it is characterised in that the halide salt is Sodium Chloride, potassium chloride and chlorine
Change one or more in zinc.
9. the pharmaceutical composition any one of a kind of claim 1 to 8 is in answering that preparation is used in the medicine of wound healing
With.
10. a kind of pharmaceutical preparation, including container, it is characterised in that be packaged with any one of claim 1 to 8 in the container
There is no chemical reaction between described pharmaceutical composition, and the container and described pharmaceutical composition.
A kind of 11. medical binders, including binder body, it is characterised in that the side of the binder body is provided with opening, described
The encapsulation part of repeatable opening, and the medicine being loaded with the opening any one of claim 1 to 8 are provided with opening
Compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710058906.2A CN106668062A (en) | 2017-01-23 | 2017-01-23 | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710058906.2A CN106668062A (en) | 2017-01-23 | 2017-01-23 | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106668062A true CN106668062A (en) | 2017-05-17 |
Family
ID=58859141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710058906.2A Pending CN106668062A (en) | 2017-01-23 | 2017-01-23 | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106668062A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096276A (en) * | 2018-03-08 | 2018-06-01 | 上海宁璋医疗器械有限公司 | A kind of debridement healing washing lotion and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2501480Y (en) * | 2001-08-03 | 2002-07-24 | 黄志良 | Bandage with dressing |
| EP1813290A1 (en) * | 2004-01-30 | 2007-08-01 | Insense Limited | Skin dressings comprising hydrated hydrogel lactate ions and glucose |
| CN201316355Y (en) * | 2008-12-18 | 2009-09-30 | 甘肃奇正藏药有限公司 | Bag-type medicine bandage |
-
2017
- 2017-01-23 CN CN201710058906.2A patent/CN106668062A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2501480Y (en) * | 2001-08-03 | 2002-07-24 | 黄志良 | Bandage with dressing |
| EP1813290A1 (en) * | 2004-01-30 | 2007-08-01 | Insense Limited | Skin dressings comprising hydrated hydrogel lactate ions and glucose |
| CN201316355Y (en) * | 2008-12-18 | 2009-09-30 | 甘肃奇正藏药有限公司 | Bag-type medicine bandage |
Non-Patent Citations (2)
| Title |
|---|
| 陈立夏，等: "PVP碘-硫酸锌喷剂对小鼠伤口愈合的影响", 《杭州医学高等专科学校学报》 * |
| 马振友: "《最新皮肤科药物手册》", 30 June 2008, 世界图书出版西安公司 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096276A (en) * | 2018-03-08 | 2018-06-01 | 上海宁璋医疗器械有限公司 | A kind of debridement healing washing lotion and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Forrest | Development of wound therapy from the Dark Ages to the present | |
| White | An historical overview of the use of silver in wound management | |
| EP2525803B1 (en) | Antimicrobial agentcomprising peroxide, alcohol and chelating agent | |
| CN105012993B (en) | A kind of cation Medical Living Creature Gum antiseptic dressing and preparation method thereof | |
| CN108187132A (en) | A kind of povidone iodine hydrogel antiseptic dressing and preparation method thereof | |
| TW201143794A (en) | Inhibiting bacterial infection and biofilm formation | |
| EP2849777A1 (en) | Use of seaprose to remove bacterial biofilm | |
| JP2022111186A (en) | Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces | |
| CN113144281B (en) | Wound surface disinfection gel and preparation method thereof | |
| CN110198731B (en) | Antimicrobial composition comprising sodium dimercaptopropane sulfonate and dimethyl sulfoxide, use of the composition, and wound treatment methods using the same | |
| CN113018499A (en) | Preparation method of ozone oil-water gel composite application capable of sterilizing, resisting virus and absorbing moisture | |
| CN106668062A (en) | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage | |
| CN113645955A (en) | Stable hypochlorous acid solution and its medical and cosmetic use | |
| CN108926577A (en) | A kind of method that electric potential water is used for Wound antibiotic healing cleaning-nursing | |
| DK2170081T3 (en) | Antimicrobial preparations | |
| US6923990B2 (en) | Stabilized silver-ion amine complex compositions and methods | |
| CN109395068A (en) | A kind of refractory wound Special sterilizing liquid | |
| CN101816678A (en) | Broad-spectrum contact type hemostatic medical fungicide and preparation method thereof | |
| CN108096276A (en) | A kind of debridement healing washing lotion and its application | |
| US20180228837A1 (en) | Stable iodine solutions with medical applications | |
| Raducu et al. | Use of polyhexanidine in treating chronic wounds | |
| WO2005077402A1 (en) | Honey based gel formulations | |
| CN110198721B (en) | Antibacterial composition containing polyvinylpyrrolidone and sodium dimercaptopropanesulfonate and application thereof | |
| Wadhwa et al. | Exit-site care in peritoneal dialysis | |
| US11744249B2 (en) | Disinfectants with iodine and copper complexes for use against coronavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170517 |